Homology Medicines Inc. Stock News

Analysts forecast that Homology Medicines Inc (NASDAQ:FIXX) will announce $680,000.00 in sales for the current quarter, Zacks reports. Two analysts have made estimates for Homology Medicines’ earnin

BioMarin (BMRN) plans to file regulatory applications seeking approval for its achondroplasia candidate, vosoritide, in the third quarter of 2020.

BioMarin (BMRN) plans to file regulatory applications seeking approval for its achondroplasia candidate, vosoritide, in the third quarter of 2020.

In a report released today, Michelle Gilson from Canaccord Genuity reiterated a Buy rating on Homology Medicines (FIXX), with a price target of $37.00.

In a report released today, Michelle Gilson from Canaccord Genuity reiterated a Buy rating on Homology Medicines ( FIXX – Research Report ), with a price target of $37.00 . The company’s shares cl

Canaccord Genuity analyst Michelle Gilson maintained a Buy rating on Homology Medicines (FIXX) on April 3 and set a price target of $37.00. The company's

Canaccord Genuity analyst Michelle Gilson maintained a Buy rating on Homology Medicines (FIXX – Research Report) on April 3 and

Homology Medicines Inc (NASDAQ:FIXX) has been given a consensus rating of “Buy” by the ten analysts that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have

Homology Medicines (FIXX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Homology Medicines (FIXX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Homology Medicines Inc (NASDAQ:FIXX) saw a large drop in short interest in the month of March. As of March 13th, there was short interest totalling 3,588,300 shares, a drop of 5.3% from the February 2

Zacks Investment Research upgraded shares of Homology Medicines (NASDAQ:FIXX) from a hold rating to a buy rating in a report published on Tuesday, Zacks.com reports. The firm currently has $17.00 pric

Homology Medicines (NASDAQ:FIXX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday, Zacks.com reports. The firm presently ha

Bank of Montreal Can lifted its stake in Homology Medicines Inc (NASDAQ:FIXX) by 42.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,10